Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2HER2-positive Breast Cancer 2Stomach Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1Colorectal Neoplasms 1Brain Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma 1

Interventions

Oxaliplatin 24Fluorouracil 20Capecitabine 16pembrolizumab 15Nivolumab 15Leucovorin 13Trastuzumab 9fludarabine 8Paclitaxel 8Drug Therapy 8Docetaxel 8Cyclophosphamide 8S 1 (combination) 7trastuzumab deruxtecan 6Specimen Handling 6Cisplatin 6Magnetic Resonance Spectroscopy 5Bevacizumab 5zolbetuximab 4Irinotecan 4Biopsy 4zimberelimab 3sintilimab 3fludarabine phosphate 3atezolizumab 3aldesleukin 3XELOX 3Surgical Procedures, Operative 3Ramucirumab 3Radiotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × tucatinib × 90 days × Clear all
NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡